European Pharmaceutical Review
JANUARY 30, 2024
Ryzneuta (efbemalenograstim alfa) received a positive opinion from the CHMP as a medicine to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy. Additionally, a positive opinion for Niapelf (paliperidone), a generic medicine for schizophrenia was adopted in the meeting.
European Pharmaceutical Review
APRIL 3, 2023
The committee recommended granting a paediatric-use marketing authorisation (PUMA) for Pedmarqsi (sodium thiosulfate) for preventing ototoxicity induced by cisplatin chemotherapy. Ototoxicity is the development of hearing or balance problems due to a medicine. Cisplatin is a chemotherapy used to treat several types of cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 6, 2022
The latter brought in acute myeloid leukaemia (AML) and cholangiocarcinoma therapy Tibsovo (ivosidenib), which was approved as a first-line therapy for AML last year in combination with Bristol-Myers Squibb’s chemotherapy Vidaza (azacitidine), dramatically expanding the eligible patient population for the drug.
BuzzRx
FEBRUARY 6, 2023
However, triggers outside the digestive system can also result in nausea or vomiting, such as pregnancy-associated nausea (morning sickness), chemotherapy-associated nausea, and nausea caused by motion sickness, inner ear problems, migraine headaches, head injuries, brain infections, or tumors. Cannabinoids Examples: Nabilone.
European Pharmaceutical Review
DECEMBER 19, 2022
The group adopted a positive opinion for Tremelimumab AstraZeneca (tremelimumab), to treat metastatic non-small cell lung cancer (NSCLC) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy. This rare genetic disorder causes muscle weakness and is often fatal.
Expert insights. Personalized for you.
96 
Let's personalize your content